Bio-techne CORP 8-K filings

Bio-Techne Corporation announced its fourth quarter and full year fiscal 2026 results, highlighting a 3% organic revenue increase in Q4 and confirming its acquisition by Merck KGaA for $73 per share.

Merck KGaA, Darmstadt, Germany, has entered into a definitive agreement to acquire Bio-Techne Corporation for $73 per share in cash.

Bio-Techne Corporation announced its third quarter fiscal year 2026 financial results, reporting a 2% decrease in revenue to $311.4 million, while also declaring a quarterly dividend of $0.08 per share.

Bio-Techne Corporation announces a key leadership transition, appointing Steve Crouse as President of its Diagnostics and Spatial Biology Segment, succeeding Dr. Matt McManus.

Bio-Techne Corporation announced flat revenue growth but increased GAAP and adjusted earnings per share for its second fiscal quarter ended December 31, 2025, alongside a quarterly cash dividend.

Bio-Techne Corporation announced its first quarter fiscal 2026 financial results, reporting a 1% revenue decrease and flat adjusted EPS, alongside the declaration of a $0.08 per share cash dividend.

Bio-Techne Corporation reported mixed fourth quarter and full-year fiscal 2025 results, highlighted by a strategic divestiture and strong adjusted earnings growth despite GAAP losses.

Bio-Techne Corporation announces Q3 FY2025 results with a 6% organic revenue increase and a new $500 million share repurchase program.

Bio-Techne Corporation authorized a new share repurchase program of up to $500 million, replacing its previous authorization from February 2, 2022.

An arbitrator ruled in favor of former Bio-Techne CEO Charles Kummeth, requiring the company to pay him approximately $37.2 million related to a dispute over stock options.

Bio-Techne announces positive Q2 FY2025 results with 9% organic revenue growth and the appointment of Dr. Amy Herr to its Board of Directors.

Bio-Techne Corporation granted a one-time restricted stock unit award to its CFO, James Hippel, for retention purposes.

Bio-Techne's first quarter fiscal 2025 results show a 5% increase in revenue, driven by strong growth in the Diagnostics & Spatial Biology segment, but a decrease in GAAP earnings per share.

Bio-Techne's fourth quarter results show a slight revenue increase but a decrease in earnings per share, alongside the announcement of a $0.08 per share dividend.

Bio-Techne reported a 3% increase in third-quarter revenue, with a 2% organic growth, alongside a decrease in GAAP and adjusted EPS, while also announcing a cash dividend of $0.08 per share.

Bio-Techne Corporation has appointed Dr. Judith Klimovsky as an independent director, temporarily expanding the board to eleven members.

Bio-Techne's second quarter fiscal 2024 results show a slight revenue decrease and a drop in earnings per share, while the company also announced a cash dividend of $0.08 per share.